Pregabalin, marketed primarily as Lyrica by Pfizer, generated significant revenue, with global sales reaching approximately $5 billion in 2018 [1]. However, sales have declined following patent expirations and the subsequent market entry of generic versions [1][2]. By 2020, Lyrica's sales had fallen to around $2.2 billion, reflecting the impact of generic competition [2].
How long has pregabalin been available?
Pregabalin was first approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of epilepsy [3]. Its indications later expanded to include neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, as well as fibromyalgia [3].
When did pregabalin patents start expiring?
The primary composition of matter patent for pregabalin (Lyrica) expired in the United States in late 2018 [1][4]. Other patents covering specific uses or formulations have different expiration dates, but the key patent that provided market exclusivity for the original drug expired in 2018 [4].
What is the impact of generic pregabalin on sales?
The expiration of patents allowed generic manufacturers to enter the market, leading to a substantial decrease in the sales of branded pregabalin (Lyrica) [1][2]. This is a common trend in the pharmaceutical industry where the introduction of generics significantly drives down prices and market share for the originator product.
Who are the main competitors for pregabalin?
Following patent expiry, numerous companies began producing and marketing generic versions of pregabalin, making it a competitive market [2]. While specific competitors vary by region and time, any pharmaceutical company with the capability to produce generic versions of pregabalin is a competitor to the original brand.
What are the approved uses for pregabalin?
Pregabalin is approved for several medical conditions. These include adjunct therapy for partial seizures in adults, treatment of neuropathic pain associated with diabetic peripheral neuropathy, treatment of postherpetic neuralgia, and management of fibromyalgia [3].
Can pregabalin be used for off-label purposes?
While pregabalin has established approved uses, physicians may prescribe it for conditions not explicitly listed on its label, which is known as off-label use. However, such uses are not supported by formal FDA approval and are based on clinical judgment and emerging research.
Where can I find more information on drug patent expirations?
Information regarding drug patent expirations, including those for pregabalin, can often be found on specialized pharmaceutical data and analytics websites. DrugPatentWatch.com provides resources and data on drug patents and their expiration timelines [1][4].